Overview
Dr. Laura Rosenberger is an Associate Professor of Surgery, where she has a high-volume breast surgical oncology practice and enjoys all aspects of an academic career. She has clinical expertise and research interest in rare breast cancers, including sarcomas and a specific focus on phyllodes tumors. Dr. Rosenberger is the founding and coordinating Principal Investigator of multiple, multi-institutional studies, including a funded prospective germline testing study, and an actively accruing rare breast tumor registry with tissue biorepository. She has authored, or co-authored, over 75 peer-reviewed publications, and serves on multiple national committees including a member of the National Comprehensive Cancer Network, or NCCN, Breast Cancer Panel.
Current Appointments & Affiliations
Recent Publications
ASO Visual Abstract: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).
Conference Ann Surg Oncol · April 2025 Full text Link to item CiteASO Visual Abstract: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).
Journal Article Annals of surgical oncology · April 2025 Full text CiteRisk Stratification for Sentinel Lymph Node Positivity in Older Women With Early-Stage Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Neu-Negative Invasive Breast Cancer.
Journal Article JCO Clin Cancer Inform · March 2025 PURPOSE: Guidelines recommend omission of sentinel lymph node biopsy (SLNB) for axillary staging in select patients age 70 years and older with early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 neu-negative (HER2-) inva ... Full text Link to item CiteRecent Grants
Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2024 - 2027View All Grants